Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice

Cancer Research

Volumn 67, Issue 15, 2007, Pages 7139-7146

  Parikh, Chaitali ^a   Subrahmanyam, Ramesh ^a,b   Ren, Ruibao ^a  

^a BRANDEIS UNIVERSITY   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; CELL MEMBRANE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DISEASE SEVERITY; GENE ACTIVATION; GENETIC TRANSDUCTION; LEUKEMIA; LEUKEMOGENESIS; MOUSE; MUTATION; MYELOID LEUKEMIA; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; PATHOGENESIS; PRIORITY JOURNAL;

ANIMALS; BLOTTING, SOUTHERN; BONE MARROW; BONE MARROW TRANSPLANTATION; DISEASE MODELS, ANIMAL; FEMALE; FLOW CYTOMETRY; GENES, RAS; HUMANS; LEUKEMIA, MYELOID; MICE; MICE, INBRED BALB C; MUTATION; NEOPLASM INVASIVENESS; RETROVIRIDAE;

EID: 34547621066     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0778     Document Type: Article

References (31)

1. Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ. Increasing complexity of Ras signaling. Oncogene 1998;17:1395-413.
2. Khosravi-Far R, Campbell S, Rossman KL, Der CJ. Increasing complexity of Ras signal transduction: involvement of Rho family proteins. Adv Cancer Res 1998;72:57-107.
3. Hancock JF. Ras proteins: different signals from different locations. Nat Rev Mol Cell Biol 2003;4:373-84.
4. Rocks O, Peyker A, Bastiaens PI. Spatio-temporal segregation of Ras signals: one ship, three anchors, many harbors. Curr Opin Cell Biol 2006;18:351-7.
5. Voice JK, Klemke RL, Le A, Jackson JH. Four human ras homologs differ in their abilities to activate Raf-1, induce transformation, and stimulate cell motility. J Biol Chem 1999;274:17164-70.
6. Walsh AB, Bar-Sagi D. Differential activation of the Rac pathway by Ha-Ras and K-Ras. J Biol Chem 2001;276:15609-15.
7. Yan J, Roy S, Apolloni A, Lane A, Hancock JF. Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase. J Biol Chem 1998;273:24052-6.
8. Maher J, Baker DA, Manning M, Dibb NJ, Roberts IA. Evidence for cell-specific differences in transformation by N-, H- and K-ras. Oncogene 1995;11:1639-47.
9. Esteban LM, Vicario-Abejon C, Fernandez-Salguero P, et al. Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mouse growth and development. Mol Cell Biol 2001;21:1444-52.
10. Koera K, Nakamura K, Nakao K, et al. K-ras is essential for the development of the mouse embryo. Oncogene 1997;15:1151-9.
11. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9.
12. Hawley RG, Fong AZ, Ngan BY, Hawley TS. Hematopoietic transforming potential of activated ras in chimeric mice. Oncogene 1995;11:1113-23.
13. Sinn E, Muller W, Pattengale P, Tepler I, Wallace R, Leder P. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell 1987;49:465-75.
14. Haupt Y, Harris AW, Adams JM. Retroviral infection accelerates T lymphomagenesis in E mu-N-ras transgenic mice by activating c-myc or N-myc. Oncogene 1992;7:981-6.
15. Kogan SC, Lagasse E, Atwater S, et al. The PEBP2βMYH11 fusion created by Inv(16)(p13;q22) in myeloid leukemia impairs neutrophil maturation and contributes to granulocytic dysplasia. Proc Natl Acad Sci U S A 1998;95:11863-8.
16. MacKenzie KL, Dolnikov A, Millington M, Shounan Y, Symonds G. Mutant N-ras induces myeloproliferative disorders and apoptosis in bone marrow repopulated mice. Blood 1999;93:2043-56.
17. Braun BS, Tuveson DA, Kong N, et al. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci U S A 2004;101:597-602.
18. Chan IT, Kutok JL, Williams IR, et al. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest 2004;113:528-38.
19. Parikh C, Subrahmanyam R, Ren R. Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice. Blood 2006;108:2349-57.
20. Gross AW, Zhang X, Ren R. Bcr-Abl with an SH3 deletion retains the ability To induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy. Mol Cell Biol 1999;19:6918-28.
21. Zhang X, Ren R. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood 1998;92:3829-40.
22. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev 2003;3:330-8.
23. Bowen DT, Frew ME, Hills R, et al. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Blood 2005;106:2113-9.
24. Aoki Y, Niihori T, Kawame H, et al. Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet 2005;37:1038-40.
25. Shen WP, Aldrich TH, Venta-Perez G, Franza BR, Jr., Furth ME. Expression of normal and mutant ras proteins in human acute leukemia. Oncogene 1987;1:157-65.
26. Maruyama C, Tomisawa M, Wakana S, et al. Overexpression of human H-ras transgene is responsible for tumors induced by chemical carcinogens in mice. Oncol Rep 2001;8:233-7.
27. Gougopoulou DM, Kiaris H, Ergazaki M, Anagnostopoulos NI, Grigoraki V, Spandidos DA. Mutations and expression of the ras family genes in leukemias. Stem Cells 1996;14:725-9.
28. Stirewalt DL, Appelbaum FR, Willman CL, Zager RA, Banker DE. Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression. Leuk Res 2003;27:133-45.
29. Cox AD, Der CJ. The dark side of Ras: regulation of apoptosis. Oncogene 2003;22:8999-9006.
30. Luo H, Li Q, O'Neal J, Kreisel F, Le Beau MM, Tomasson MH. c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations. Blood 2005;106:2452-61.
31. Shields JM, Pruitt K, McFall A, Shaub A, Der CJ. Understanding Ras: "it ain't over 'til it's over". Trends Cell Biol 2000;10:147-54